• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

29 monoclonal antibody drugs marketed in China

XiaoyaowanNovember 13, 2018

Tag: china , Monoclonal Antibody Drugs

China’s monoclonal antibody market is far behind the European and American developed countries no matter in terms of sales scale or product quantity and variety; compared to global market, size of China’s monoclonal antibody market is still small, and is estimated to account for about 1% of global monoclonal antibody market. FDA approved a total of 77 monoclonal antibody drugs by the end of 2017, including 7 monoclonal antibody biosimilars, while the number of monoclonal antibody drugs approved for marketing in China has reached 29, including 19 imported monoclonal antibody drugs and 10 Chinese-produced monoclonal antibody drugs.

Generic name

Trade name

Manufacturer

Marketing time in China

Rituximab

Rituxan

Roche

2000

Trastuzumab

Herceptin

Roche

2002

Basiliximab

Simulect

Novartis

2003

Cetuximab

Erbitux

Merck

2005

Infliximab

Remicade

J & J

2007

Bevacizumab

Avastin

Roche

2010

Adalimumab

Humira

AbbVie

2010

Etanercept

Enbrel

Pfizer

2010

Ranibizumab

Lucentis

Novartis

2011

Tocilizumab

Actemra

Roche

2013

Omalizumab

Xolair

Roche

2017

Ustekinumab

Stelara

J & J

2017

Golimumab

Simponi

J & J

2018

Aflibercept

Eylea

Bayer

2018

Idarucizumab

Praxbind

Boehringer Ingelheim

2018

Nivolumab

Opdivo

BMS

2018

Pembrolizumab

Keytruda

Merck

2018

Evolocumab

Repatha

Amgen

2018

Eculizumab

Soliris

Alexion

2018

Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion

Yisaipu

CP Guojian Pharm

2006

Iodine[131I] tumor necrosis human/mouse chimeric monoclonal antibody

Vivatuxin

MediPharm Biotech

2007

Nimotuzumab

Taixinsheng

Biotech Pharma

2008

Muromomab

/

Wuhan Institute of Biological Products

2010

Anti-human IL-8 monoclonal antibody

Abcream

Asia Space Pharmaceutical [Dalian]

2010

Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion

Qiangke

Celgen Biopharma

2011

Dalizumab

Jiannipai

CP Guojian Pharm

2011

Iodine[131I] metuximab

Likating

Huasun Biotechnology

2011

Conbercept

Langmu

Kanghong Pharmaceutical

2013

Recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion

Anbainuo

Hisun Pharmaceutical

2015
 
Read More:
 
 

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Previous:Amazing Monthly Sales Performance of Opdivo and Keytruda in China

Next:Monoclonal antibody drugs in development in China

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

29 monoclonal antibody drugs marketed in China | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

Factory supply China manufacturer Olive leaf extract/ Oleuropein 10%-60% /CAS 32619-42-4

Factory supply China manufacturer Olive leaf extract/ Oleuropein 10%-60% /CAS 32619-42-4
Echinacea Purpurea Extract

Echinacea Purpurea Extract
Nomegestrol ≥99.0% Hormone API made in china

Nomegestrol ≥99.0% Hormone API made in china
China Factory N-Acetyl-L-Tyrosine Fast Delivery

China Factory N-Acetyl-L-Tyrosine Fast Delivery
Zeaxanthin 5% supplier Plant extract made in china

Zeaxanthin 5% supplier Plant extract made in china
Palmatine CP2010 Plant extract Pharmaceutical supplier made in china

Palmatine CP2010 Plant extract Pharmaceutical supplier made in china
Methyldopa sesquihydrate USP CEP DMF Pharmaceutical API Antihypertensive drugs made in china

Methyldopa sesquihydrate USP CEP DMF Pharmaceutical API Antihypertensive drugs made in china
Sulfadiazine USP/BPsupplier API Pharmaceutical Sulfonamides made in china

Sulfadiazine USP/BPsupplier API Pharmaceutical Sulfonamides made in china
Soybean oil 10%~40%Plant extract Pharmaceutical made in china

Soybean oil 10%~40%Plant extract Pharmaceutical made in china
Argireline ≥95.0% HPLC Pharmaceutical API Polypeptide made in china

Argireline ≥95.0% HPLC Pharmaceutical API Polypeptide made in china

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service